RGLS Projected Dividend Yield
Com Par $0.001/Regulus Therapeutics Inc ( NASDAQ : RGLS )Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. Co. is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. Co. is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. 21 YEAR PERFORMANCE RESULTS |
RGLS Dividend History Detail RGLS Dividend News RGLS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |